---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-26-000004"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:44:49.608362+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend

## Summary
- Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.
- FY2025 net loss of $59.0M vs $70.8M in FY2024; operating expenses fell 18% to $66.8M.
- Cash and investments $156.1M as of Dec 31, 2025; management sees sufficient runway through 2027.
- Early Access Program launched Jan 2026 for Tau proteoforms; no material revenue expected in FY2026.
- FY2026 operating expenses expected to increase 15-20% YoY; full commercial launch targeted late 2026.

## SEC filing metadata
- accession: 0001808805-26-000004
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000004/0001808805-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880526000004/naut-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-26-000004
- JSON: https://secwatch.observer/filing/0001808805-26-000004.json
- Plain text: https://secwatch.observer/filing/0001808805-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.